AcelRx Pharmaceuticals submits Zalviso NDA to FDA AcelRx Pharmaceuticals.

Other researchers who contributed to the scholarly study include, Sara Moore, BS, Division of Psychiatry and Behavioral Sciences at Emory University School of Medicine and C. Monica Capra, PhD, the Section of Economics and the Center for Neuropolicy, Emory University.. AcelRx Pharmaceuticals submits Zalviso NDA to FDA AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical firm focused on the advancement and commercialization of innovative treatments for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application to the U.S. Zalviso is a patient-activated, noninvasive analgesic system, which delivers 15 mcg sufentanil per dose as needed for pain control, subject to a 20 minute lockout period between dosages.To learn more about how you can take action, visit or email get in touch. The abstract, titled ‘Initial Results of a Phase I/II Study Evaluating the utmost Tolerated Dose, Pharmacokinetics, Basic safety, and Efficacy of Hyperthermia and Lyso-Thermosensitive Liposomal Doxorubicin in Sufferers with Breast Cancer Recurrence at the Upper body Wall ,’ will be provided by Brigid O’Connor, M.D., Ph.D., business lead clinical investigator from the Rhode Island Medical center in Providence, RI.